| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ILK; ILK1; ILK2; Integrin-linked protein kinase; 59 kDa serine/threonine-protein kinase; ILK-1; ILK-2; p59ILK |
| Entrez GeneID | 3611 |
| WB Predicted band size | Calculated MW: 51 kDa; Observed MW: 51 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human ILK |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Integrin-Linked Kinase(ILK)抗体的3篇参考文献及其摘要概括：
1. **"Role of integrin-linked kinase in cancer progression and metastasis"**
- **作者**: Hannigan GE, et al.
- **摘要**: 本文探讨ILK在肿瘤侵袭和转移中的关键作用，通过特异性抗体抑制ILK活性，发现其调控细胞外基质信号通路，促进肿瘤细胞迁移和存活。
2. **"Integrin-linked kinase regulates endothelial cell survival and tumor angiogenesis"**
- **作者**: Troussard AA, et al.
- **摘要**: 研究利用ILK抗体阻断内皮细胞中的ILK功能，发现ILK缺失导致血管生成减少，提示其在肿瘤血管形成中的重要性。
3. **"ILK modulates epithelial polarity and matrix metalloproteinase activity in fibrotic lung disease"**
- **作者**: White DE, et al.
- **摘要**: 通过免疫组化与ILK抗体检测肺纤维化模型，发现ILK激活促进上皮-间质转化(EMT)，并增强基质金属蛋白酶表达，驱动纤维化进展。
4. **"Targeting integrin-linked kinase suppresses proliferation and invasiveness of ovarian cancer cells"**
- **作者**: Ahmed N, et al.
- **摘要**: 使用ILK抗体及基因沉默技术，证明抑制ILK可降低卵巢癌细胞增殖和侵袭能力，为靶向治疗提供实验依据。
以上文献均涉及ILK抗体的实验应用(如Western blot、免疫组化或功能抑制)，并聚焦于ILK在肿瘤、纤维化等病理过程中的调控机制。
Integrin-linked kinase (ILK) is a multifunctional serine/threonine protein kinase that serves as a critical mediator in integrin-mediated cell-matrix adhesion and signaling. It interacts directly with the cytoplasmic domains of β1. β2. and β3 integrin subunits, forming a scaffold for signaling complexes that regulate cell survival, proliferation, migration, and epithelial-mesenchymal transition (EMT). ILK also modulates cytoskeletal dynamics by linking integrins to actin-binding proteins like PINCH and parvin, collectively forming the IPP complex. Dysregulation of ILK expression or activity is implicated in cancer progression, fibrosis, and cardiovascular diseases, making it a focus of therapeutic research.
Antibodies targeting ILK are essential tools for studying its expression, localization, and function in physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP) to detect ILK protein levels, assess its interaction partners, or evaluate signaling pathways in cell lines, tissues, or disease models. Validated ILK antibodies typically exhibit specificity for conserved epitopes across species (e.g., human, mouse, rat) and distinguish between phosphorylated and non-phosphorylated forms when required. Commercially available ILK antibodies are often raised against recombinant full-length proteins or specific peptide sequences, with clones from hosts like rabbit or mouse. Quality control includes validation via knockout/knockdown cell lines or recombinant protein assays. Research utilizing these antibodies has advanced understanding of ILK's role in tumor metastasis, tissue fibrosis, and cardiac remodeling, highlighting its potential as a diagnostic marker or therapeutic target.
×
